Mannkind (MNKD) Cash from Investing Activities (2010 - 2026)
Mannkind (MNKD) reported Cash from Investing Activities of $18.7 million for Q1 2026, up 214.07% year-over-year from $6.0 million in Q1 2025, and up 106.41% quarter-over-quarter from -$292.0 million in Q4 2025.
Mannkind (MNKD) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Cash from Investing Activities data on file, last reported at $18.7 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at $18.7 million, up 214.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$292.0 million (down 591.22% YoY), and the FY2025 annual result was -$304.8 million, down 215.37% from the prior year.
- Cash from Investing Activities advanced to $18.7 million in Q1 2026 per MNKD's latest filing, from -$292.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $48.2 million in Q4 2024 and troughed at -$292.0 million in Q4 2025.
- A 5-year average of -$22.3 million and a median of $2.0 million in 2022 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 710.82% in 2024 and fell as far as 1606.0% in 2024.
- A 5-year view of Cash from Investing Activities shows it stood at $15.0 million in 2022, then slumped by 152.6% to -$7.9 million in 2023, then jumped by 710.82% to $48.2 million in 2024, then sank by 705.43% to -$292.0 million in 2025, then surged by 106.41% to $18.7 million in 2026.
- Business Quant data shows MNKD's Cash from Investing Activities at $18.7 million in Q1 2026, -$292.0 million in Q4 2025, and -$25.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Mannkind | 1.21 Bn | 1.08 Bn | 82.66 Mn | 18.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.73 Mn |
| Mar 31, 2026 | 18.73 Mn |
| Dec 31, 2025 | -291.96 Mn |
| Dec 31, 2025 | -291.96 Mn |
| Sep 30, 2025 | -25.06 Mn |
| Sep 30, 2025 | -25.06 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Mar 31, 2025 | 5.96 Mn |
| Dec 31, 2024 | 48.22 Mn |
| Dec 31, 2024 | 48.22 Mn |
| Sep 30, 2024 | -41.26 Mn |
| Sep 30, 2024 | -41.26 Mn |
| Jun 30, 2024 | -55.18 Mn |
| Jun 30, 2024 | -55.18 Mn |
| Mar 31, 2024 | -48.44 Mn |
| Mar 31, 2024 | -48.44 Mn |
| Dec 31, 2023 | -7.90 Mn |
| Dec 31, 2023 | -7.90 Mn |